Compare Illumina, Inc. (ILMN) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs The Coca-Cola Co K — how do they compare? Illumina, Inc. trades at $191.43 (market cap $27.94B), while The Coca-Cola Co K trades at $82.07 (market cap $353.32B). The key difference: The Coca-Cola Co K is far larger — about 12.6× Illumina, Inc.'s market cap, and The Coca-Cola Co K pays a 2.58% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | KO | |
|---|---|---|
Market Cap | $27.94B | $353.32B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $84.92 |
52-Week Low | $91.00 | $65.67 |
Enterprise Value | $29.33B | $383.39B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Coca-Cola (KO) trades at $82.05, up 0.6% with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. Recent quarterly EPS exceeded expectations, while analyst consensus is bullish with a $90.67 price target. The company maintains robust cash flow and a 64-year dividend growth streak, supported by stable demand trends noted by Bank of America on April 10, 2026.
Outlook remains positive due to valuation upside and dividend reliability, though technical resistance near $83 and high debt levels pose risks. Investors benefit from defensive positioning amid market volatility, but must monitor regional demand fluctuations and interest rate impacts on borrowing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
